Tandem Diabetes Care (TNDM) is back in focus after recent share price swings, with the stock closing at US$16.87. Investors are weighing mixed return figures and fresh financial data on revenue and ...
15 analysts have shared their evaluations of Tandem Diabetes Care (NASDAQ:TNDM) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...
Helping toddlers manage their Type 1 diabetes—typically a difficult task, due to their constant growth and development, not to mention fussiness—may now be a bit easier. The FDA has expanded its ...
Tandem Diabetes Care, Inc. TNDM shares rallied 7.7% in the last trading session to close at $17.53. This move can be ...
Tandem Diabetes Care has strong insulin-pump tech, but ongoing losses and cash burn threaten viability. Click here to read ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...
CEO John Sheridan highlighted that Tandem achieved over 20% growth for the third consecutive quarter, with record sales both in the U.S. and internationally. The company's operational focus on ...
StockStory.org on MSN
Tandem Diabetes’s (NASDAQ:TNDM) Q2 CY2026 earnings results: Revenue in line with expectations
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) in Q2 CY2026, with sales up 5.8% year on year to $254.6 million. The company’s outlook for the full year was close to analysts’ estimates ...
For its fourth quarter of 2023, Tandem Diabetes' revenue declined 10.8% year over year to $196.8 million, translating to a net loss of $30 million, or $0.46 per share. Adjusted for nonrecurring items, ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results